Comprehensive Hypersomnia Pipeline and Therapeutic Landscape Analysis 2025

According to DelveInsight's evaluation, globally, the Hypersomnia pipeline comprises over 3 key pharmaceutical firms continuously advancing more than 4 Hypersomnia treatment therapies, with analysis of Clinical Trials, Therapeutics, Mechanism of Action, Route of Administration, and Developments conducted by DelveInsight.

"Hypersomnia Pipeline Analysis, 2025" report by DelveInsight outlines comprehensive intelligence into the current clinical development scenario and growth prospects across the Hypersomnia Market.

The Hypersomnia Pipeline analysis encompasses in-depth commercial and clinical evaluation of the pipeline products from the preclinical developmental phase to the marketed phase. The analysis also covers a comprehensive description of the medication, including the mechanism of action of the therapeutic, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Primary Highlights from the Hypersomnia Pipeline Analysis:

https://www.delveinsight.com/sample-request/hypersomnia-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

• Pharmaceutical firms across the globe are diligently advancing toward developing novel Hypersomnia treatment therapies with a considerable amount of success over recent years.

• Hypersomnia pharmaceutical firms operating in the treatment market include Avadel Pharmaceuticals, Zevra Therapeutics, Alkermes, among others, are creating therapies for Hypersomnia management.

• Emerging Hypersomnia investigational medications in the different phases of clinical trials including Lumryz, KP1077, ALKS 2680, among others, are anticipated to have a significant impact on the Hypersomnia market in the forthcoming years.

• In November 2024, Axsome Therapeutics disclosed that its investigational narcolepsy treatment, AXS-12 (reboxetine), successfully achieved the primary endpoint in a Phase III ENCORE trial (NCT05059223). As a norepinephrine reuptake inhibitor and cortical dopamine modulator, AXS-12 demonstrated a 72% reduction in cataplexy attacks after one month and an 82% reduction at six months.

• In April 2025, Irish biopharmaceutical company Alkermes initiated a randomized Phase II investigation to evaluate the safety profile and efficacy of ALKS 2680 in adults with idiopathic hypersomnia (IH). The double-blind, placebo-controlled Vibrance-3 trial plans to enroll approximately 96 IH patients across sites in the US, Europe, and Australia. Participants will be randomly assigned to receive either 10 mg, 14 mg, or 18 mg of ALKS 2680, or a placebo, once daily for a duration of eight weeks.

• In April 2025, iNGENū CRO, a specialized Contract Research Organization with extensive experience in sleep medicine, revealed that two clinical trials for rare and severe sleep disorders-Idiopathic Hypersomnia and Narcolepsy-have obtained ethics approval and are now open for patient enrollment. These key investigations are being led by Dr. Sud Agarwal, Specialist Anaesthesiologist and Clinical Research Physician at iNGENū CRO.

Hypersomnia Background

Hypersomnia is a sleep disorder distinguished by excessive daytime sleepiness (EDS) despite receiving adequate or prolonged sleep at night. Individuals with hypersomnia often struggle to remain awake during the day, resulting in difficulties in work, school, and daily activities. The condition can be primary (idiopathic hypersomnia) or secondary to other medical conditions such as sleep apnea, narcolepsy, depression, or neurological disorders. Treatment typically involves lifestyle modifications, stimulant medications, or addressing underlying causes.

Access a Free Sample PDF Report to learn more about Hypersomnia Pipeline Therapeutic Evaluation- https://www.delveinsight.com/sample-request/hypersomnia-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Emerging Hypersomnia Investigational Medications Under Different Phases of Clinical Development Include:

• Lumryz: Avadel Pharmaceuticals

• KP1077: Zevra Therapeutics

• ALKS 2680: Alkermes

Hypersomnia Administration Method

The Hypersomnia pipeline analysis presents therapeutic evaluation of the pipeline medications by Administration Method. Products are classified under various administration routes, such as:

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Hypersomnia Molecular Classification

Hypersomnia products are classified under various molecular categories, such as:

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Hypersomnia Pipeline Therapeutics Evaluation

• Hypersomnia Evaluation by Product Category

• Hypersomnia By Stage and Product Category

• Hypersomnia Evaluation by Administration Method

• Hypersomnia By Stage and Administration Method

• Hypersomnia Evaluation by Molecular Classification

• Hypersomnia by Stage and Molecular Classification

DelveInsight's Hypersomnia Analysis covers approximately 4+ products under different phases of clinical development including:

• Late-phase products (Phase III)

• Mid-phase products (Phase II)

• Early-phase product (Phase I)

• Preclinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Administration Method

Further Hypersomnia product details are provided in the analysis. Access the Hypersomnia pipeline analysis to learn more about the emerging Hypersomnia therapies https://www.delveinsight.com/sample-request/hypersomnia-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Major Pharmaceutical Firms in the Hypersomnia Therapeutics Market Include:

Key pharmaceutical firms developing therapies for Hypersomnia include Axsome Therapeutics, Alkermes, Zevra Therapeutics, Takeda, Aexon Labs, among others.

Hypersomnia Pipeline Analysis:

The Hypersomnia pipeline analysis offers intelligence into:

• The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Hypersomnia management, including cumulative therapies created by each organization for this indication.

• It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Hypersomnia Treatment.

• Hypersomnia key pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.

• Hypersomnia investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.

• Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Hypersomnia market.

The analysis is constructed using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, among others.

Access Sample PDF Report to learn more about Hypersomnia medications and therapies https://www.delveinsight.com/sample-request/hypersomnia-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Hypersomnia Pipeline Market Drivers

• Increased Awareness and Diagnosis, Unmet Medical Need, Rising Prevalence, Advances in Neuroscience and Drug Development, Growing Investment in Research and Development (R&D), Supportive Regulatory Environment, are some of the important factors that are fueling the Hypersomnia Market.

Hypersomnia Pipeline Market Obstacles

• However, Lack of Clear Biomarkers, High Clinical Trial Costs, Regulatory Hurdles, Limited Patient Population, Efficacy and Safety Concerns, Market Competition, and other factors are creating obstacles in the Hypersomnia Market growth.

Scope of Hypersomnia Pipeline Drug Intelligence

• Coverage: Global

• Key Hypersomnia Pharmaceutical Firms: Avadel Pharmaceuticals, Zevra Therapeutics, Alkermes, among others

• Key Hypersomnia Investigational Treatments: Lumryz, KP1077, ALKS 2680, among others

• Hypersomnia Therapeutic Evaluation: Hypersomnia current marketed and Hypersomnia emerging therapies

• Hypersomnia Market Dynamics: Hypersomnia market drivers and Hypersomnia market obstacles

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com